Insider Sell: CFO Robert Andrade Sells 30,000 Shares of Fennec Pharmaceuticals Inc
Robert Andrade, the Chief Financial Officer of Fennec Pharmaceuticals Inc (NASDAQ:FENC), has sold 30,000 shares of the company on January 5, 2024, according to a recent SEC Filing. This transaction has been part of a series of sales by the insider over the past year, with a total of 55,000 shares sold and no shares purchased.
Fennec Pharmaceuticals Inc is a biopharmaceutical company focused on the development of PEDMARK (a unique formulation of sodium thiosulfate), which is designed to reduce the incidence of hearing loss in pediatric cancer patients being treated with platinum-based chemotherapy.
The insider transaction history at Fennec Pharmaceuticals Inc reveals a pattern of insider sales with no insider buys over the past year. There have been 10 insider sells and 0 insider buys during this period.
On the date of the insider's most recent transaction, shares of Fennec Pharmaceuticals Inc were trading at $10.53, giving the company a market cap of $303.168 million.
The insider's recent sale is part of a broader trend of insider transactions at Fennec Pharmaceuticals Inc, which market observers often scrutinize for insights into a company's performance and management's perspective on the stock's valuation.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
